Kobayashi Taku
Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan.
Inflamm Intest Dis. 2021 Aug 10;7(1):59-63. doi: 10.1159/000517961. eCollection 2022 Jan.
Crohn's disease may cause a life-long disease burden in many aspects due to its progressive nature. A large proportion of refractory patients have been benefiting from scheduled maintenance anti-TNF treatment; therefore, strategy to stop anti-TNF agents in Crohn's disease is not widely conducted. There have been observational studies demonstrating that approximately half of the patients relapse within a year after discontinuation. Several factors have been suggested as potential predictors for relapse; however, a consensus has not been reached so far. Although most relapse can be rescued by the re-treatment with the same anti-TNF agent, a proportion of patients may result in progressive bowel damage and the need for surgery. Therefore, an attempt to stop anti-TNF is not recommended without careful discussion, even if they are in long-term remission.
克罗恩病因其进展性本质,可能在许多方面导致终身疾病负担。很大一部分难治性患者已从定期维持性抗TNF治疗中获益;因此,在克罗恩病中停用抗TNF药物的策略并未广泛实施。有观察性研究表明,大约一半的患者在停药后一年内复发。有几个因素被认为是复发的潜在预测因素;然而,迄今为止尚未达成共识。虽然大多数复发可以通过重新使用相同的抗TNF药物进行治疗来挽救,但一部分患者可能会导致肠道进行性损伤并需要手术。因此,即使患者处于长期缓解期,在没有仔细讨论的情况下,也不建议尝试停用抗TNF药物。